{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+3+ML+IM+Injection&page=2",
    "query": {
      "intervention": "Normal Saline 3 ML IM Injection",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+3+ML+IM+Injection&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T14:48:03.293Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00752050",
      "title": "Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Rhytides",
        "Frown Lines Between the Eyebrows"
      ],
      "interventions": [
        {
          "name": "Mentor Purified Toxin Botulinum Toxin Type A",
          "type": "DRUG"
        },
        {
          "name": "Preservative-free Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mentor Worldwide, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 699,
      "start_date": "2007-11",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2011-09-12",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 1,
      "location_summary": "Santa Barbara, California",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00752050"
    },
    {
      "nct_id": "NCT00752297",
      "title": "Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Rhytides"
      ],
      "interventions": [
        {
          "name": "Preservative-free Saline",
          "type": "DRUG"
        },
        {
          "name": "Mentor Purified Toxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mentor Worldwide, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2007-06",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2011-09-12",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 1,
      "location_summary": "Santa Barbara, California",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00752297"
    },
    {
      "nct_id": "NCT01238276",
      "title": "Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Infection, Soft Tissue",
        "Infection, Wound",
        "Cellulitis",
        "Diabetic Foot Ulcer"
      ],
      "interventions": [
        {
          "name": "Cefazolin",
          "type": "DRUG"
        },
        {
          "name": "Silberg Tissue Preparation System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sonescence, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-10-23",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 1,
      "location_summary": "Sebastopol, California",
      "locations": [
        {
          "city": "Sebastopol",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01238276"
    },
    {
      "nct_id": "NCT02076178",
      "title": "Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "744 Tablet",
          "type": "DRUG"
        },
        {
          "name": "744 LA Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 127,
      "start_date": "2014-03-27",
      "completion_date": "2016-02-23",
      "has_results": true,
      "last_update_posted_date": "2017-12-15",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076178"
    },
    {
      "nct_id": "NCT04199689",
      "title": "Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Papillomavirus Infections"
      ],
      "interventions": [
        {
          "name": "9vHPV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Saline for Injection)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "20 Years to 45 Years · Male only"
      },
      "enrollment_count": 6033,
      "start_date": "2020-02-27",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-25",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 32,
      "location_summary": "Northridge, California • Rialto, California • Simi Valley, California + 28 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Simi Valley",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199689"
    },
    {
      "nct_id": "NCT03307915",
      "title": "A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos4.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-Mosaic",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140 + Mosaic gp140",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 25,
      "start_date": "2018-03-05",
      "completion_date": "2021-11-05",
      "has_results": false,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03307915"
    },
    {
      "nct_id": "NCT02117570",
      "title": "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Associated Disease"
      ],
      "interventions": [
        {
          "name": "Clostridium difficile vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 185,
      "start_date": "2014-07",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 12,
      "location_summary": "DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Norfolk",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02117570"
    },
    {
      "nct_id": "NCT02030301",
      "title": "Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "VCL-HB01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VCL-HM01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PBS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 165,
      "start_date": "2013-12",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02030301"
    },
    {
      "nct_id": "NCT00664417",
      "title": "Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza",
        "Orthomyxoviridae Infections"
      ],
      "interventions": [
        {
          "name": "Monovalent subvirion H5N1 influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Physiological saline",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 375,
      "start_date": "2008-04",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2012-04-17",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 6,
      "location_summary": "San Diego, California • South Miami, Florida • Springfield, Missouri + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00664417"
    },
    {
      "nct_id": "NCT02543268",
      "title": "A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.ZEBOV-Batch #1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.ZEBOV-Batch #2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.ZEBOV-Batch #3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-BN-Filo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 329,
      "start_date": "2015-09-21",
      "completion_date": "2016-07-20",
      "has_results": false,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-09-28T14:48:03.293Z",
      "location_count": 6,
      "location_summary": "Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Mishawaka",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543268"
    }
  ]
}